%0 Journal Article
%T Baseline findings of a multicentric ambispective cohort study (2021-2022) among hospitalised mucormycosis patients in India.
%A Abdulkader RS
%A Ponnaiah M
%A Bhatnagar T
%A S D
%A Rozario AGA
%A K G
%A Mohan M
%A E M
%A Saravanakumar D
%A Moorthy A
%A Tyagi AK
%A Parmar BD
%A Devaraja K
%A Medikeri G
%A Ojah J
%A Srivastava K
%A K K
%A Das N
%A B N
%A Sharma P
%A Kumar Parida P
%A Kumar Saravanam P
%A Kulkarni P
%A S P
%A Patil S P
%A Kumar Bagla R
%A D R
%A S Melkundi R
%A S Satpute S
%A Narayanan S
%A Jahagirdar S
%A Dube S
%A Kumar Panigrahi S
%A Babu D S
%A Saini V
%A Singh Saxena R
%A Srivastava A
%A Chandra Baishya A
%A Garg A
%A Kumar Mishra A
%A Jyoti Talukdar A
%A Kankaria A
%A Karat A
%A Sundaresh Kumar A
%A Chug A
%A Vankundre A
%A Ramaswamy B
%A Mb B
%A R Jadav B
%A Dhiwakar M
%A Ghate G
%A Shah HV
%A Saha I
%A Sivapuram K
%A J Joshi K
%A Singh M
%A Chand Bairwa M
%A K D
%A K K
%A E M
%A Samagh N
%A Dinakaran N
%A Gupta N
%A Gupta N
%A M Nagarkar N
%A Solanki N
%A Kumar Panda P
%A Bachalli P
%A Shanbag R
%A Patil R
%A Kumar A R
%A Narayan Patil R
%A Thookkanaickenpalayam Vijayaraghavan R
%A Hanumantappa R
%A A R
%A Mandal SK
%A Kishve SP
%A Varghese Thomas S
%A Sarkar S
%A Thakur S
%A Patil S
%A Lakshmanan S
%A D Rao S
%A V S
%A Nayak T
%A Dixit UR
%A B U
%A Backiavathy V
%A Shenoy V
%A Hallur VK
%A Bhatnagar A
%A Murhekar MV
%J Mycology
%V 15
%N 1
%D 2024
%M 38558844
暂无%R 10.1080/21501203.2023.2271928
%X In India, the incidence of mucormycosis reached high levels during 2021-2022, coinciding with the COVID-19 pandemic. In response to this, we established a multicentric ambispective cohort of patients hospitalised with mucormycosis across India. In this paper, we report their baseline profile, clinical characteristics and outcomes at discharge. Patients hospitalized for mucormycosis during March-July 2021 were included. Mucormycosis was diagnosed based on mycological confirmation on direct microscopy (KOH/Calcofluor white stain), culture, histopathology, or supportive evidence from endoscopy or imaging. After consent, trained data collectors used medical records and telephonic interviews to capture data in a pre-tested structured questionnaire. At baseline, we recruited 686 patients from 26 study hospitals, of whom 72.3% were males, 78% had a prior history of diabetes, 53.2% had a history of corticosteroid treatment, and 80% were associated with COVID-19. Pain, numbness or swelling of the face were the commonest symptoms (73.3%). Liposomal Amphotericin B was the commonest drug formulation used (67.1%), and endoscopic sinus surgery was the most common surgical procedure (73.6%). At discharge, the disease was stable in 43.3%, in regression for 29.9% but 9.6% died during hospitalization. Among survivors, commonly reported disabilities included facial disfigurement (18.4%) and difficulties in chewing/swallowing (17.8%). Though the risk of mortality was only 1 in 10, the disability due to the disease was very high. This cohort study could enhance our understanding of the disease's clinical progression and help frame standard treatment guidelines.